Ole H.
- Country
- Denmark
- Department
- Lungemedicinsk afdeling
Research Overview
- Long-term safety and efficacy of subcutaneous lunsekimig in adults with asthma: An open-label extension study
- Efficacy and Safety of Early Depemokimab Initiation as Add-on Therapy in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
- Weekly IV human alpha1‑proteinase inhibitor at multiple doses for safety and effectiveness in adults with alpha1 antitrypsin deficiency‑related emphysema
Data & Insights
Has run more than one trial at 392 of 825 partner sites.
Specializations
Respiratory Disease Management
The investigator specializes in treating various chronic respiratory conditions, with particular emphasis on developing innovative therapeutic approaches for common and rare pulmonary disorders.
- Asthma treatment optimization
- COPD management strategies
- Bronchiectasis interventions
Focus includes evaluating novel therapeutic agents for patients with uncontrolled respiratory conditions requiring advanced treatment options.
Rare Pulmonary Disorders
Expertise in treating rare pulmonary conditions with specialized focus on developing therapeutic solutions for complex respiratory disorders.
- Pulmonary sarcoidosis treatment
- Alpha-1 antitrypsin deficiency management
- Nontuberculous mycobacterial infections
Specializes in evaluating innovative treatments for patients with rare respiratory conditions requiring targeted therapeutic approaches.
Advanced Respiratory Therapeutics
Focuses on innovative respiratory treatments including biological therapies and novel drug delivery systems for various pulmonary conditions.
- Biological therapy applications
- Inhalation treatment systems
- Combination therapy approaches
Investigates cutting-edge therapeutic options for patients with severe or treatment-resistant respiratory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.